Skip to main content
Top
Published in: Clinical and Experimental Nephrology 1/2014

01-02-2014 | Original Article

Small renal size in newborns with spina bifida: possible causes

Authors: Paolo Montaldo, Luisa Montaldo, Azzurra Concetta Iossa, Marina Cennamo, Elisabetta Caredda, Roberto Del Gado

Published in: Clinical and Experimental Nephrology | Issue 1/2014

Login to get access

Abstract

Background

Previous studies reported that children with neural tube defects, but without any history of intrinsic renal diseases, have small kidneys when compared with age-matched standard renal growth. The aim of this study was to investigate the possible causes of small renal size in children with spina bifida by comparing growth hormone deficiency, physical limitations and hyperhomocysteinemia.

Methods

The sample included 187 newborns with spina bifida. Renal sizes in the patients were assessed by using maximum measurement of renal length and the measurements were compared by using the Sutherland monogram. According to the results, the sample was divided into two groups—a group of 120 patients with small kidneys (under the third percentile) and a control group of 67 newborns with normal kidney size. Plasma total homocysteine was investigated in mothers and in their children. Serum insulin-like growth factor-1 (IGF-1) levels were measured.

Results

Serum IGF-1 levels were normal in both groups. Children and mothers with homocysteine levels >10 μmol/l were more than twice as likely to have small kidneys and to give to birth children with small kidneys, respectively, compared with newborns and mothers with homocysteine levels <10 μmol/l. An inverse correlation was also found between the homocysteine levels of mothers and kidney sizes of children (r = − 0.6109 P ≤ 0.01).

Conclusions

It is highly important for mothers with hyperhomocysteinemia to be educated about benefits of folate supplementation in order to reduce the risk of small renal size and lower renal function in children.
Literature
1.
go back to reference Sutherland RW, Wiener JS, Roth DR, Gonzales ET Jr. A renal size nomogram for the patient with myelomeningocele. J Urol. 1997;158:1265–7.PubMedCrossRef Sutherland RW, Wiener JS, Roth DR, Gonzales ET Jr. A renal size nomogram for the patient with myelomeningocele. J Urol. 1997;158:1265–7.PubMedCrossRef
2.
go back to reference Gross GW, Thornburg AJ, Bellinger MF. Normal renal growth in children with myelodysplasia. Am J Roentgenol. 1986;146:615–7.CrossRef Gross GW, Thornburg AJ, Bellinger MF. Normal renal growth in children with myelodysplasia. Am J Roentgenol. 1986;146:615–7.CrossRef
3.
go back to reference Del Gado R, Perrone L, Del Gaizo D, et al. Renal size and function in patients with neuropathic bladder due to myelomeningocele: the role of growth hormone. J Urol. 2003;170:1960–1.PubMedCrossRef Del Gado R, Perrone L, Del Gaizo D, et al. Renal size and function in patients with neuropathic bladder due to myelomeningocele: the role of growth hormone. J Urol. 2003;170:1960–1.PubMedCrossRef
4.
go back to reference Rotenstein D, Breen TJ. Growth hormone treatment of children with myelomeningocele. J Pediatr. 1996;128:S28–31.PubMedCrossRef Rotenstein D, Breen TJ. Growth hormone treatment of children with myelomeningocele. J Pediatr. 1996;128:S28–31.PubMedCrossRef
5.
go back to reference Herrmann W. The importance of hyperhomocysteinemia as a risk factor for diseases: an overview. Clin Chem Lab Med. 2001;39:666–74.PubMed Herrmann W. The importance of hyperhomocysteinemia as a risk factor for diseases: an overview. Clin Chem Lab Med. 2001;39:666–74.PubMed
6.
go back to reference Carlo WA. The fetus and the neonatal infant. In: Kliegman RM, Stanton B, St. Geme J, Schor N, Behrman RE, editors. Nelson textbook of pediatrics. 19th ed. Philadelphia: Saunders; 2011. p. 532. Carlo WA. The fetus and the neonatal infant. In: Kliegman RM, Stanton B, St. Geme J, Schor N, Behrman RE, editors. Nelson textbook of pediatrics. 19th ed. Philadelphia: Saunders; 2011. p. 532.
7.
go back to reference Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;422:43–52.PubMedCrossRef Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;422:43–52.PubMedCrossRef
8.
go back to reference Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629–37.PubMedCrossRef Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629–37.PubMedCrossRef
9.
go back to reference Filler G, Gharib M, Casier S, Lödige P, Ehrich JH, Dave S. Prevention of chronic kidney disease in spina bifida. Int Urol Nephrol. 2011;44:817–27.PubMedCrossRef Filler G, Gharib M, Casier S, Lödige P, Ehrich JH, Dave S. Prevention of chronic kidney disease in spina bifida. Int Urol Nephrol. 2011;44:817–27.PubMedCrossRef
10.
go back to reference Felkner M, Suarez L, Canfield MA, Brender JD, Sun Q. Maternal serum homocysteine and risk for neural tube defects in a Texas-Mexico border population. Birth Defects Res A Clin Mol Teratol. 2009;85:574–81.PubMedCrossRef Felkner M, Suarez L, Canfield MA, Brender JD, Sun Q. Maternal serum homocysteine and risk for neural tube defects in a Texas-Mexico border population. Birth Defects Res A Clin Mol Teratol. 2009;85:574–81.PubMedCrossRef
11.
go back to reference van der Put NM, Thomas CM, Eskes TK, Trijbels FJ, Steegers-Theunissen RP, Mariman EC, et al. Altered folate and vitamin B12 metabolism in families with spina bifida offspring. QJM. 1997;90:505–10.PubMedCrossRef van der Put NM, Thomas CM, Eskes TK, Trijbels FJ, Steegers-Theunissen RP, Mariman EC, et al. Altered folate and vitamin B12 metabolism in families with spina bifida offspring. QJM. 1997;90:505–10.PubMedCrossRef
12.
go back to reference Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr. 2000;71:62–8. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr. 2000;71:62–8.
13.
go back to reference Khong T, Hague W. The placenta in maternal hyperhomocysteinaemia. Br J Obstet Gynaecol. 1999;106:273–8.PubMedCrossRef Khong T, Hague W. The placenta in maternal hyperhomocysteinaemia. Br J Obstet Gynaecol. 1999;106:273–8.PubMedCrossRef
14.
go back to reference Wilson RD, Johnson JA, Wyatt P, Allen V, Gagnon A, Langlois S, et al. Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can. 2007;29:1003–26.PubMed Wilson RD, Johnson JA, Wyatt P, Allen V, Gagnon A, Langlois S, et al. Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can. 2007;29:1003–26.PubMed
15.
go back to reference Blencowe H, Cousens S, Modell B, Lawn J. Folic acid to reduce neonatal mortality from neural tube disorders. Int J Epidemiol. 2010;39:110–21.CrossRef Blencowe H, Cousens S, Modell B, Lawn J. Folic acid to reduce neonatal mortality from neural tube disorders. Int J Epidemiol. 2010;39:110–21.CrossRef
16.
go back to reference Wiltshire EJ, Couper JJ. Improved folate status in children and adolescents during voluntary fortification of food with folate. J Paediatr Child Health. 2004;40:44–7.PubMedCrossRef Wiltshire EJ, Couper JJ. Improved folate status in children and adolescents during voluntary fortification of food with folate. J Paediatr Child Health. 2004;40:44–7.PubMedCrossRef
Metadata
Title
Small renal size in newborns with spina bifida: possible causes
Authors
Paolo Montaldo
Luisa Montaldo
Azzurra Concetta Iossa
Marina Cennamo
Elisabetta Caredda
Roberto Del Gado
Publication date
01-02-2014
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 1/2014
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0802-z

Other articles of this Issue 1/2014

Clinical and Experimental Nephrology 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine